1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
Delayed Hong Kong Stock Exchange  -  11:10 2022-08-15 pm EDT
70.50 HKD   +0.28%
08/12WuXi Biologics Inc. Announces Change of Address of Principal Place of Business in Hong Kong
CI
08/05Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy
MT
07/22China’s Wuxi AppTec, Wuxi Biologics to Each Invest $1.4 Billion in Singapore
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wuxi Biologics takes step to getting off U.S. 'unverified' trade list

07/05/2022 | 07:00am EDT

NEW YORK, July 5 (Reuters) - Wuxi Biologics, a Chinese company that makes ingredients for AstraZeneca's COVID-19 vaccine, may be a step closer to being taken off a U.S. trade list that it landed on five months ago, wiping HK$77 billion($9.9 billion) off its market value at the time.

Chinese authorities allowed a U.S. export control officer to conduct inspections of at least one company in the city of Wuxi last week, a U.S. Commerce Department official said.

The official declined to identify the company or companies involved, but a person familiar with the matter told Reuters a check was conducted last week at Wuxi Biologics.

If the U.S. deems the check favorable, it could be removed from the list.

The company did not respond to requests for comment. Shares in Wuxi Biologics jumped as much as 12.2%, its highest since Jan. 24, on Tuesday after the news.

Wuxi Biologics units in Wuxi and Shanghai were among 33 entities added to the U.S. Commerce Department's "Unverified List" in February. The company was one of only two added to the list with addresses in Wuxi.

The United States placed the entities on the list because it could not conduct on-site inspections to verify information related to them and U.S. items shipped to them.

The resumption of inspections is seen by the United States as a positive development amid increased tensions with China over a range of issues, including the U.S. blocking of imports linked to forced labor in China and the possible delisting of Chinese companies that don't meet audit requirements.

Last week, there also were renewed threats to shut down SMIC, China's top chipmaker, if it is found to be supplying Russia in violation of U.S. export controls.

"I do have some good news," the Commerce Department official, who could not be identified publicly, told a conference on export controls in Washington on Thursday.

"We were able to get some end-use check movement this week in Wuxi."

The official added that hopefully a U.S. export control officer would be able to go into another province, Anhui, in the coming weeks, though that could be delayed by fresh COVID-19 outbreaks.

U.S. inspections of Chinese companies require approval and scheduling by China's commerce ministry, the U.S. official said.

China's zero tolerance COVID-19 protocols account for most of the delay over the last couple of years, though there were some opportunities to have conducted checks, the official said.

"Covid aside, it's really dependent on them to agree to schedule the pending end-use checks that we have," the official said.

China's commerce ministry did not respond to a request for comment.

In February, U.S. Assistant Commerce Secretary Matthew Axelod said the additions to the list "signal to the PRC government the importance of their cooperation in scheduling end-use checks."

But China's Ministry of Commerce slammed the development and said Washington should correct its "wrongdoings," return to the track of cooperation and contribute more to the global economic recovery.

During an investor day on June 16, Wuxi Biologics said that it hoped to see the "unverified list" issue resolved for at least one of its units by September, and for the other by the end of the year.

The company said it had initially expected an inspection in April, which was disrupted by COVID-19. It said it had not seen a significant impact on actual operations from being added to the list.

U.S. exporters can engage with parties on the unverified list, but are required to conduct additional due diligence before they can ship goods to them, and may need to apply for more licenses.

Citi analysts said in a report on Tuesday that the company's management had noted the result of the checks could be positive but that they were still waiting for final confirmation.

"In our view, the potential removal of Wuxi site from the (unverified list) would help alleviate market concerns on geopolitical risk and boost market sentiment on the CRO (contract research organisation) sector," they said. (Reporting by Karen Freifeld; Additional reporting by Roxanne Liu in Beijing and Brenda Goh in Shanghai. Edited by Kenneth Li, Deepa Babington and Sonali Desai)


© Reuters 2022
All news about WUXI BIOLOGICS (CAYMAN) INC.
08/12WuXi Biologics Inc. Announces Change of Address of Principal Place of Business in Hong ..
CI
08/05Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy
MT
07/22China’s Wuxi AppTec, Wuxi Biologics to Each Invest $1.4 Billion in Singapore
MT
07/19WuXi Biologics Sees Up to 38% Jump in H1 Profit
MT
07/18WuXi Biologics Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022
CI
07/08WUXI BIOLOGICS CAYMAN : XDC and AbTis Sign Memorandum of Understanding for Development and..
PU
07/07WuXi Biologics launches cGMP microbial products facility in Hangzhou
AQ
07/06Wuxi Biologics Nears Removal From US ‘Unverified' Trade List
MT
07/05GLOBAL MARKETS LIVE : J Sainsbury, Foxconn, JPMorgan, Comcast, Tesla...
MS
07/05Wuxi Biologics takes step to getting off U.S. 'unverified' trade list
RE
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2022 15 100 M 2 229 M 2 229 M
Net income 2022 4 685 M 692 M 692 M
Net cash 2022 6 116 M 903 M 903 M
P/E ratio 2022 55,0x
Yield 2022 -
Capitalization 259 B 38 248 M 38 248 M
EV / Sales 2022 16,8x
EV / Sales 2023 12,1x
Nbr of Employees 9 864
Free-Float 84,5%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Last Close Price 60,75 CNY
Average target price 95,27 CNY
Spread / Average Target 56,8%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director